Ano Kaisha no Shikumi
Search
Menu

Kubota Pharmaceutical

Kubota Pharmaceutical Holdings Co., Ltd.

Company highlights

Average annual salary ¥5.35 million; average length of service 1.9 years.

Key figures

Period Jan 2025 to Dec 2025ConsolidatedIFRS

RevenueDisclosed ¥21,335,000
Operating marginCalculated -4194.3%
Net assets to total assetsCalculated 91.6%

Company profile

Securities code 4596 / EDINET code E32854 / Pharmaceuticals / Fiscal year end December 31

千代田区霞が関３丁目７番１号／Capital stock ¥1,000 million
Address, capital stock, fiscal year end and industry: the FSA’s EDINET code list.

Company details
窪田 良 Representative

Tables scroll sideways

Disclosed data

Source: Annual Securities Report (Jan 2025 to Dec 2025) · filed 2026-03-27

Profitability ★☆☆☆☆position among all companies -4194.3%
Growth (revenue, 3-year average) ★★★★★position among all companies 37.2%
Capital efficiency ★☆☆☆☆position among all companies -42.2%

Business activities and revenue composition

Revenue and profit by business segment

Disclosed segments (business divisions used in reporting): one

Revenue and profit

Amounts by account
GroupAccountAmountConsolidated / Non-consolidated
Selling, general and administrative expenses Selling general and administrative expenses IFRS ¥0.5 billion Consolidated
General and administrative expenses ¥0.5 billion Parent only
Commission fees ¥0.2 billion Parent only
Research and development expenses ¥0.2 billion Parent only
Payrolls and allowances ¥99.73 million Parent only
Directors' compensations ¥27.65 million Parent only
Profit by stage Operating income ¥-0.9 billion Consolidated
Ordinary income ¥-0.7 billion Parent only
Net income ¥-0.7 billion Consolidated

Kubota Pharmaceutical

Selling, general and administrative expenses

Period Jan 2025 to Dec 2025Source Annual securities reports

Selling general and administrative expenses IFRS ¥0.5 billion (33.2%)33%General and administrative expenses ¥0.5 billion (31.5%)31%Commission fees ¥0.2 billion (14.4%)14%Research and development expenses ¥0.2 billion (13.1%)13%Payrolls and allowances ¥0.1 billion (6.1%)6%Directors' compensations ¥0.0 billion (1.7%)¥1.6B
  • Selling general and administrative expenses IFRS　¥0.5 billion
  • General and administrative expenses　¥0.5 billion
  • Commission fees　¥0.2 billion
  • Research and development expenses　¥0.2 billion
  • Payrolls and allowances　¥0.1 billion
  • Directors' compensations　¥0.0 billion

Performance, financial position and capital allocation

Finance
91.6% Net assets to total assets Industry median 69.7% FY ending 12/2025 · consolidated / calculated
-34.2% Return on assets (ROA)
¥11.47 Net assets per share
¥-0.6 billion Free cash flow
¥2.0 billion Total assets

Long-term changes in performance

Period 2016 to 2025Disclosed

Revenue ×0.03 from 2016 to 2025

Kubota Pharmaceutical

Long-term revenue, profit and asset trends

Period 2016 to 2025Source Annual securities reportsDisclosed

Mark on the chart
1 -1 -2 -4 2016 2018 2020 2022 2024 2025 Net sales and operating revenue Profit before tax 2023　Revenue (IFRS) year on year +383.2%, Profit (loss) before tax (IFRS) as a share of revenue +20,688.8 points 2024　Revenue (IFRS) year on year -31.8%, Profit (loss) before tax (IFRS) as a share of revenue -1,167.6 points 2025　Revenue (IFRS) year on year -21.5%, Profit (loss) before tax (IFRS) as a share of revenue +1,732.5 points 0Latest value 2025 0¥ billion 1Highest in the period shown 2016 1¥ billion 0Lowest in the period shown 2022 0¥ billion ¥ billion

Recent performance trends

Year-on-year comparison

Period 2015 to 2025Disclosed

Item20212022202320242025
Revenue (IFRS) Could not be retrieved ¥0.0B ¥0.0B ¥0.0B ¥0.0B
Year on year (%) Could not be retrieved Could not be retrieved +383.2%◆ -31.8%◆ -21.5%◆
Profit (loss) before tax (IFRS) -¥2.6B -¥2.0B -¥1.5B -¥1.3B -¥0.7B
Change from prior year 1.07x 0.77x 0.74x 0.89x 0.51x
Profit (loss) before tax (IFRS) as a share of Revenue (IFRS) Could not be retrieved -24,423.4% -3,734.6% -4,902.2% -3,169.7%
Change (percentage points) Could not be retrieved Could not be retrieved +20,688.8 points◆ -1,167.6 points◆ +1,732.5 points◆

Fiscal periods marked for changes

  • 2023Revenue (IFRS) year on year +383.2%, Profit (loss) before tax (IFRS) as a share of revenue +20,688.8 points
  • 2024Revenue (IFRS) year on year -31.8%, Profit (loss) before tax (IFRS) as a share of revenue -1,167.6 points
  • 2025Revenue (IFRS) year on year -21.5%, Profit (loss) before tax (IFRS) as a share of revenue +1,732.5 points

Kubota Pharmaceutical

Earnings and net assets per share over time

Unit yenSource Annual securities reports

-11 -26 -42 -57 4 years ago 3 years ago 2 years ago Last year This year Earnings per share yen 91 60 30 0 4 years ago 3 years ago 2 years ago Last year This year Net assets per share yen
Consolidated indicators (15 items)
Item4 years ago3 years ago2 years agoLast yearThis year
Revenue (IFRS) Could not be retrieved ¥8.25 million ¥39.89 million ¥27.19 million ¥21.34 million
Profit (loss) before tax (IFRS) ¥-2.6 billion ¥-2.0 billion ¥-1.5 billion ¥-1.3 billion ¥-0.7 billion
Profit (loss) attributable to owners of parent (IFRS) ¥-2.6 billion ¥-2.0 billion ¥-1.5 billion ¥-1.3 billion ¥-0.7 billion
Comprehensive income attributable to owners of parent (IFRS) ¥-2.2 billion ¥-1.7 billion ¥-1.5 billion ¥-1.3 billion ¥-0.7 billion
Equity attributable to owners of parent (IFRS) ¥4.2 billion ¥3.9 billion ¥2.6 billion ¥1.4 billion ¥1.8 billion
Total assets (IFRS) ¥4.8 billion ¥4.4 billion ¥3.0 billion ¥1.5 billion ¥2.0 billion
Equity attributable to owners of parent per share (IFRS) 90.55 yen 72.31 yen 47.21 yen 24.48 yen 15.72 yen
Basic earnings (loss) per share (IFRS) -57.46 yen -40.92 yen -26.79 yen -23.65 yen -10.59 yen
Diluted earnings (loss) per share (IFRS) -57.46 yen -40.92 yen -26.79 yen -23.65 yen -10.59 yen
Ratio of equity attributable to owners of parent (IFRS) 85.9% 89.4% 87.7% 90.1% 91.6%
Return on equity attributable to owners of parent (IFRS) -51.6% -49.8% -45.2% -66.0% -42.2%
Net cash provided by (used in) operating activities (IFRS) ¥-2.5 billion ¥-2.1 billion ¥-1.3 billion ¥-1.2 billion ¥-0.6 billion
Net cash provided by (used in) investing activities (IFRS) ¥3.6 billion ¥0.5 billion ¥-45.03 million ¥-43.06 million ¥-3.65 million
Net cash provided by (used in) financing activities (IFRS) ¥0.2 billion ¥1.4 billion ¥96.58 million ¥-88.27 million ¥1.1 billion
Cash and cash equivalents (IFRS) ¥4.0 billion ¥4.0 billion ¥2.8 billion ¥1.5 billion ¥1.9 billion
Parent only indicators (12 items)
Item4 years ago3 years ago2 years agoLast yearThis year
Operating revenue ¥0.2 billion ¥0.2 billion ¥0.2 billion ¥0.3 billion ¥35.81 million
Ordinary income (loss) ¥-96.23 million ¥-42.26 million ¥-0.7 billion ¥-1.3 billion ¥-0.7 billion
Net income (loss) ¥-53.54 million ¥0.53 million ¥-0.7 billion ¥-1.3 billion ¥-0.7 billion
Capital stock ¥1.3 billion ¥2.1 billion ¥2.1 billion ¥33.96 million ¥0.6 billion
Total number of issued shares (common stock) 45,861,688 shares 54,622,588 shares 56,062,988 shares 56,765,588 shares 115,404,288 shares
Net assets ¥2.0 billion ¥3.4 billion ¥2.9 billion ¥1.6 billion ¥2.0 billion
Total assets ¥2.0 billion ¥3.5 billion ¥2.9 billion ¥1.7 billion ¥2.1 billion
Net assets per share 28.35 yen 51.56 yen 39.94 yen 17.34 yen 11.47 yen
Basic earnings (loss) per share -1.18 yen 0.01 yen -13.06 yen -23.12 yen -11.71 yen
Diluted earnings per share Could not be retrieved 0.01 yen Could not be retrieved Could not be retrieved Could not be retrieved
Equity-to-asset ratio 65.3% 80.8% 76.6% 59.0% 63.4%
Return on equity Could not be retrieved 0.0% Could not be retrieved Could not be retrieved Could not be retrieved

Research and development expenses and capital expenditure

Source: R&D and capital expenditure sections, annual securities reports · 4 years (2019 to 2025)Disclosed

¥0.3 billion Research and development
¥30.93 million Capital expenditure
Fiscal year Research and development Capital expenditure
FY ending 12/2025 ¥0.3 billion ¥30.93 million
FY ending 12/2024 ¥0.5 billion Could not be retrieved
FY ending 12/2020 ¥2.0 billion ¥0.2 billion
FY ending 12/2019 ¥2.8 billion Could not be retrieved

Revenue scale in the same industry

Kubota Pharmaceutical

Source Annual securities reports of each company

Pharmaceuticals: 68 companies · revenue · largest first・each company’s latest fiscal year・consolidated (parent-only where no consolidated figures)・Disclosed

Workforce information

Source: Annual Securities Report (Jan 2025 to Dec 2025)Parent-onlyDisclosed

7 Employees (parent only) Industry median 94
47.6 Average age Industry median 44.3
1.9 years Average length of service Industry median 9.6 years
¥5.35 million Average annual salary Industry median ¥8.24 million
People and organisation
2.7¥ million Sales per employee Industry median 38.4¥ million FY ending 12/2025 · consolidated / calculated
¥-111.86 million Operating income per employee

Audit and disclosure information

Annual securities report, year ended 2025-12-31Disclosed

ItemValue
Audit firm 三優監査法人
Audit fees (this year, total) ¥32.00 million
Non-audit fees (this year, total) Not applicable
Going concern note Cannot be determined
Accounting standard IFRS

See the book series →

Sources and methodology

Retrieved disclosed figures

Accounts and values from the annual securities report, by section

Major management indicators (5 years) (25 items)

ItemValueConsolidated / Non-consolidated
Net cash provided by (used in) operating activities (IFRS) ¥-0.6 billion Consolidated
Basic earnings (loss) per share (IFRS) -10.59 yen Consolidated
Revenue (IFRS) ¥21.34 million Consolidated
Diluted earnings (loss) per share (IFRS) -10.59 yen Consolidated
Profit (loss) attributable to owners of parent (IFRS) ¥-0.7 billion Consolidated
Comprehensive income attributable to owners of parent (IFRS) ¥-0.7 billion Consolidated
Net cash provided by (used in) investing activities (IFRS) ¥-3.65 million Consolidated
Cash and cash equivalents (IFRS) ¥1.9 billion Consolidated
Profit (loss) before tax (IFRS) ¥-0.7 billion Consolidated
Total assets (IFRS) ¥2.0 billion Consolidated
Equity attributable to owners of parent (IFRS) ¥1.8 billion Consolidated
Return on equity attributable to owners of parent (IFRS) -42.2% Consolidated
Ratio of equity attributable to owners of parent (IFRS) 91.6% Consolidated
Net cash provided by (used in) financing activities (IFRS) ¥1.1 billion Consolidated
Equity attributable to owners of parent per share (IFRS) 15.72 yen Consolidated
Operating revenue ¥35.81 million Parent only
Net income (loss) ¥-0.7 billion Parent only
Total number of issued shares (common stock) 115,404,288 shares Parent only
Net assets ¥2.0 billion Parent only
Ordinary income (loss) ¥-0.7 billion Parent only
Total assets ¥2.1 billion Parent only
Equity-to-asset ratio 63.4% Parent only
Capital stock ¥0.6 billion Parent only
Basic earnings (loss) per share -11.71 yen Parent only
Net assets per share 11.47 yen Parent only

Employees (7 items)

ItemValueConsolidated / Non-consolidated
Number of employees 8 people Consolidated
Number of employees 8 people Consolidated
Average length of service (years) 1.88 years Parent only
Average annual salary ¥5.35 million Parent only
Average age (years) 47.6 years old Parent only
Number of employees 7 people Parent only
Number of employees 7 people Parent only

Shares (1 items)

ItemValueConsolidated / Non-consolidated
Total shareholder return 16.9% Parent only

Other disclosed items (1 items)

ItemValueConsolidated / Non-consolidated
Total return on the share price index 56.4% Parent only

Research and development (1 items)

ItemValueConsolidated / Non-consolidated
Research and development expenses ¥0.3 billion Consolidated

Property and facilities (1 items)

ItemValueConsolidated / Non-consolidated
Capital expenditures ¥30.93 million Consolidated

Audit (2 items)

ItemValueConsolidated / Non-consolidated
Fees for audit and attestation services - reporting company ¥32.00 million Consolidated
Fees for audit and attestation services - total ¥32.00 million Consolidated

Balance sheet (68 items)

ItemValueConsolidated / Non-consolidated
Other current liabilities clifrs ¥2.75 million Consolidated
Other current assets caifrs ¥46.27 million Consolidated
Other components of equity IFRS ¥-1.4 billion Consolidated
Other non current assets ncaifrs ¥10.46 million Consolidated
Lease obligations ¥13.99 million Consolidated
Lease obligations ¥8.25 million Consolidated
Right-of-use assets, Acquisition cost (IFRS) ¥66.10 million Consolidated
Right-of-use assets, Accumulated depreciation and impairment losses (IFRS) ¥-66.10 million Consolidated
Retained earnings IFRS ¥-25.7 billion Consolidated
Trade receivables2 caifrs ¥0.35 million Consolidated
Tools, furniture and fixtures ¥0.2 billion Consolidated
Tools, furniture and fixtures ¥-0.2 billion Consolidated
Property, plant and equipment ¥0.3 billion Consolidated
Property, plant and equipment ¥-0.3 billion Consolidated
Inventories ¥3.76 million Consolidated
Total current liabilities IFRS ¥0.2 billion Consolidated
Current assets IFRS ¥2.0 billion Consolidated
Cash and cash equivalents (IFRS) ¥1.9 billion Consolidated
Cash and cash equivalents (IFRS) ¥1.9 billion Consolidated
Net assets ¥1.8 billion Consolidated
Net assets ¥1.8 billion Consolidated
Total assets ¥2.0 billion Consolidated
Equity attributable to owners of parent (IFRS) ¥1.8 billion Consolidated
Liabilities and equity IFRS ¥2.0 billion Consolidated
Liabilities IFRS ¥0.2 billion Consolidated
Capital surplus IFRS ¥28.4 billion Consolidated
Share capital IFRS ¥0.6 billion Consolidated
Non current labilities IFRS ¥8.25 million Consolidated
Non current assets IFRS ¥10.46 million Consolidated
Other ¥1.30 million Parent only
Other ¥0.47 million Parent only
Retained earnings ¥-2.1 billion Parent only
Unearned revenue ¥2.75 million Parent only
Prepaid expenses ¥17.18 million Parent only
Non-current assets ¥0.3 billion Parent only
Tools, furniture and fixtures ¥55.45 million Parent only
Buildings ¥1.80 million Parent only
Investments and other assets ¥0.3 billion Parent only
Lease and guarantee deposits ¥7.21 million Parent only
Subscription rights to shares ¥0.6 billion Parent only
Accounts receivable - other ¥0.1 billion Parent only
Consumption taxes receivable ¥27.66 million Parent only
Income taxes payable ¥19.17 million Parent only
Accrued expenses ¥58.80 million Parent only
Accounts payable - other ¥52.40 million Parent only
Shareholders' equity ¥1.3 billion Parent only
Inventories ¥3.76 million Parent only
Current liabilities ¥0.1 billion Parent only
Current assets ¥1.7 billion Parent only
Accumulated depreciation ¥-3.68 million Parent only
Accumulated depreciation ¥-1.80 million Parent only
Goodwill ¥-51.78 million Parent only
Cash and deposits ¥1.6 billion Parent only
Net assets ¥2.0 billion Parent only
Net assets ¥2.0 billion Parent only
Total assets ¥2.1 billion Parent only
Retained earnings brought forward ¥-2.1 billion Parent only
Treasury stock ¥-0.07 million Parent only
Liabilities ¥0.1 billion Parent only
Liabilities and net assets ¥2.1 billion Parent only
Allowance for doubtful accounts ¥-10.00 million Parent only
Allowance for doubtful accounts ¥-84.66 million Parent only
Capital surplus ¥2.9 billion Parent only
Legal capital surplus ¥2.9 billion Parent only
Capital stock ¥0.6 billion Parent only
Long-term loans receivable ¥60.00 million Parent only
Shares of subsidiaries and associates ¥0.3 billion Parent only
Deposits received ¥3.32 million Parent only

Accounts unique to this company (23 items)

ItemValueConsolidated / Non-consolidated
Revenue ¥21.36 million Consolidated
Revenue ¥0.1 billion Consolidated
Revenue ¥13.64 million Consolidated
Revenue ¥21.34 million Consolidated
Revenue ¥0.9 billion Consolidated
Revenue ¥0.2 billion Consolidated
Revenue ¥-28.03 million Consolidated
Revenue ¥35.04 million Consolidated
Revenue ¥-0.2 billion Consolidated
Revenue ¥4.27 million Consolidated
Revenue ¥12.48 million Consolidated
Revenue ¥-4.12 million Consolidated
Revenue ¥-5.82 million Consolidated
Revenue ¥52.50 million Consolidated
Revenue ¥-37.53 million Consolidated
Revenue ¥1.77 million Consolidated
Revenue ¥0.2 billion Consolidated
Revenue ¥1.86 million Consolidated
Revenue ¥1.1 billion Consolidated
Revenue ¥0.2 billion Consolidated
Revenue ¥0.4 billion Consolidated
Revenue ¥8.17 million Consolidated
Revenue ¥35.04 million Consolidated

Statement of income (62 items)

ItemValueConsolidated / Non-consolidated
Other comprehensive income IFRS ¥5.92 million Consolidated
Other income and expenses net IFRS ¥0.2 billion Consolidated
Other income IFRS ¥-0.25 million Consolidated
Other operating expenses IFRS ¥36.52 million Consolidated
Other operating expenses IFRS ¥36.52 million Consolidated
Operating income ¥-0.9 billion Consolidated
Net cash provided by (used in) operating activities ¥-0.6 billion Consolidated
Exchange differences on translation of foreign operations net of tax items that may be reclassified to profit or loss ociifrs ¥5.92 million Consolidated
Exchange differences on translation of foreign operations net of tax items that may be reclassified to profit or loss ociifrs ¥5.92 million Consolidated
Rents ¥2.43 million Consolidated
Basic earnings loss per share IFRS -10.59 yen Consolidated
Cost of sales IFRS ¥26.13 million Consolidated
Outsourcing expenses ¥89.67 million Consolidated
Diluted earnings loss per share IFRS -10.59 yen Consolidated
Research and development expenditure recognized as expense during period IFRS ¥0.3 billion Consolidated
Profit loss IFRS ¥-0.7 billion Consolidated
Profit loss IFRS ¥-0.7 billion Consolidated
Profit loss IFRS ¥-0.7 billion Consolidated
Profit loss IFRS ¥-0.7 billion Consolidated
Comprehensive income (IFRS) ¥-0.7 billion Consolidated
Comprehensive income (IFRS) ¥-0.7 billion Consolidated
Net income ¥-0.7 billion Consolidated
Total transactions with owners IFRS ¥1.1 billion Consolidated
Net cash provided by (used in) investing activities (IFRS) ¥-3.65 million Consolidated
Issuance of new shares ssifrs ¥1.1 billion Consolidated
Share-based payment transactions ¥35.22 million Consolidated
Impairment loss ¥36.52 million Consolidated
Net increase decrease in cash and cash equivalents IFRS ¥0.5 billion Consolidated
Effect of exchange rate changes on cash and cash equivalents IFRS ¥-15.31 million Consolidated
Profit loss before tax IFRS ¥-0.7 billion Consolidated
Comprehensive income attributable to owners of parent IFRS ¥-0.7 billion Consolidated
Net cash provided by (used in) financing activities (IFRS) ¥1.1 billion Consolidated
Selling general and administrative expenses IFRS ¥0.5 billion Consolidated
Finance income IFRS ¥1.85 million Consolidated
Finance costs IFRS ¥0.87 million Consolidated
General and administrative expenses ¥0.5 billion Parent only
Interest income ¥2.86 million Parent only
Operating income ¥-0.7 billion Parent only
Operating revenue ¥35.81 million Parent only
Non-operating income ¥7.70 million Parent only
Non-operating expenses ¥30.03 million Parent only
Operating expenses ¥0.8 billion Parent only
Cost of sales ¥26.03 million Parent only
Net income (loss) ¥-0.7 billion Parent only
Net income (loss) ¥-0.7 billion Parent only
Directors' compensations ¥27.65 million Parent only
Commission fees ¥0.2 billion Parent only
Issuance of new shares ¥1.1 billion Parent only
Gain on reversal of share acquisition rights ¥4.29 million Parent only
Stock issuance cost ¥28.32 million Parent only
Income taxes - current ¥0.95 million Parent only
Impairment loss ¥9.68 million Parent only
Foreign exchange losses ¥1.71 million Parent only
Extraordinary income ¥4.29 million Parent only
Extraordinary loss ¥9.68 million Parent only
Research and development expenses ¥0.2 billion Parent only
Income (loss) before income taxes ¥-0.7 billion Parent only
Ordinary income ¥-0.7 billion Parent only
Payrolls and allowances-SGA ¥99.73 million Parent only
Purchase of treasury stock ¥-4,000 Parent only
Reversal of allowance for doubtful accounts ¥2.01 million Parent only
Miscellaneous income ¥2.82 million Parent only

Statement of cash flows (9 items)

ItemValueConsolidated / Non-consolidated
Repayments of lease obligations ¥-15.74 million Consolidated
Interest paid ope cfifrs ¥-0.88 million Consolidated
Subtotal ¥-0.8 billion Consolidated
Proceeds from collection of leasehold deposits and guarantee deposits inv cfifrs ¥5.12 million Consolidated
Proceeds from issuance of share acquisition rights fin cfifrs ¥0.18 million Consolidated
Purchase of property plant and equipment inv cfifrs ¥-10.63 million Consolidated
Impairment losses reversal of impairment losses ope cfifrs ¥36.52 million Consolidated
Financial revenue ¥-1.85 million Consolidated
Financial expenses ¥0.87 million Consolidated

Statement of changes in equity (2 items)

ItemValueConsolidated / Non-consolidated
Total changes during the period ¥0.4 billion Parent only
Net changes in items other than shareholders' equity ¥21.18 million Parent only
Basic indicators
ItemValueConsolidated / Non-consolidatedSource
Net cash provided by (used in) operating activities ¥-0.6 billion ConsolidatedDisclosed
Number of employees 8 ConsolidatedDisclosed
Net assets ¥1.8 billion ConsolidatedDisclosed
売上収益 ¥21.34 million ConsolidatedDisclosed
Operating income ¥-0.9 billion ConsolidatedDisclosed
Operating revenue ¥35.81 million Parent onlyDisclosed
Ordinary income ¥-0.7 billion Parent onlyDisclosed
Net income ¥-0.7 billion ConsolidatedDisclosed
Total assets ¥2.0 billion ConsolidatedDisclosed
Operating margin -4194.3%ConsolidatedCalculated
Net margin -3169.7%ConsolidatedCalculated
Sales per employee 2666875 yenConsolidatedCalculated
Total asset turnover 0.01 timesConsolidatedCalculated
Net assets to total assets 91.6%ConsolidatedCalculated
How to read the figures, and caveats

Terms

  • Consolidated: the parent company together with the subsidiaries it consolidates
  • Parent-only: the single company that filed the annual securities report
  • Calculated: a disclosed figure put through the formula shown
  • Not disclosed: no such value in the filing (not treated as zero)
  • Not retrieved: a value this page could not extract, including values in the filing that could not be matched. The same item may appear in another table
  • Segment: a business division the company uses in its disclosures
  • Industry median: the middle value among companies in the same industry that disclose the item
  • ★: position when every company is lined up by value (not a judgement of the company)See the formulas
  • Source: document name, period covered, filing date and where it was obtained
  • Tables scroll sideways

Key figures

  • Operating margin -4,194.3%　Operating income ÷ net sales 　＝ ¥-0.9 billion ÷ ¥21.34 million
    Operating income ÷ net sales. The denominator is Revenue (Consolidated, IFRS).
  • Net margin -3,169.7%　Net income ÷ net sales 　＝ ¥-0.7 billion ÷ ¥21.34 million
    Net income ÷ net sales. The denominator is Revenue (Consolidated, IFRS).
  • Sales per employee 2,666,875 yen　Sales or operating revenue ÷ employees 　＝ ¥21.34 million ÷ 8 people
    Sales or operating revenue ÷ employees. The denominator is Number of employees (Consolidated, Japanese GAAP).
  • Total asset turnover 0.01 times　Sales or operating revenue ÷ total assets 　＝ ¥21.34 million ÷ ¥2.0 billion
    Sales or operating revenue ÷ total assets. The denominator is Total assets (Consolidated, IFRS).
  • Net assets to total assets 91.6%　Net assets ÷ total assets 　＝ ¥1.8 billion ÷ ¥2.0 billion
    Net assets ÷ total assets. The denominator is Total assets (Consolidated, IFRS).

Company details

  • Representative　代表取締役会長、社長兼最高経営責任者, gBizINFO

Amounts by account

  • Totals and their component lines together; consolidated and parent-only figures mixed (right-hand column)

Selling, general and administrative expenses

  • Breakdown of selling, general and administrative expenses (costs of selling and running the company). Cost of sales not included
  • Each item: already inside the SG&A total (not added to it)

Finance

  • Net assets to total assets　Net assets ÷ total assets
  • Return on assets (ROA)　Net income ÷ total assets (consolidated)
  • Net assets per share　Parent only
  • Free cash flow　Free cash flow: operating cash flow (cash generated by the business) plus investing cash flow (asset purchases, disposals and other investments), consolidated
  • Total assets　Consolidated

Long-term changes in performance

  • Revenue　Disclosed value for 2025 ÷ disclosed value for 2016

Year-on-year comparison

  • Year on year: calculated only where the item, reporting range and accounting standard match and the periods are consecutive
  • Comparison basis not confirmed: periods with a change of accounting standard or reporting range, a moved fiscal year end, or an unconfirmed period
  • ◆: a period where revenue moved 20% or more from the prior year, profit as a share of revenue moved 2.0 percentage points or more, or profit or loss changed sign. Item used named in the table and list. Not a ranking of companies

Earnings and net assets per share over time

  • Earnings per share = net profit ÷ shares; net assets per share = net assets ÷ shares. Disclosed values from the key financial indicators of the annual securities report. No share prices used

Research and development expenses and capital expenditure

  • Research and development: total in the R&D section of the annual securities report. Capital expenditure: this year’s actual spending in the capital expenditure overview (not a plan). Years: only those available in the annual securities reports on hand (one to four per company); no row for other years.

Revenue scale in the same industry

  • Revenue (disclosed values) of companies in the same industry, using the same grouping as the industry pages. Only the top three and the two companies either side of this one. Bar length relative to the largest company (100). An order of size, not a ranking of quality

Workforce information

  • All four: the reporting company (parent-only), as disclosed in the employee section of the annual securities report. Employees across the consolidated group: 8 (a different scope, kept apart from the four above). Industry median: the middle value among companies in Pharmaceuticals that disclose the item (industries with at least 5 companies only).

People and organisation

  • Sales per employee　Net sales (or operating revenue) ÷ employees
  • Operating income per employee　Operating income ÷ employees

Audit and disclosure information

  • Whether there is a going concern note (the accounting assumption that a company will continue operating), and audit information
  • Audit firm, audit fees, going concern note and accounting standard: facts written in the latest annual securities report and the audit report filed with it (not a judgement of the company). Going concern note: “note” when the note text is present, “not applicable” when the report states nothing to report, “cannot be determined” when neither appears. Note text not reproduced. Amended filings not shown (annual securities reports only)

Data sources and calculation methods

Primary source: the annual securities report of Kubota Pharmaceutical Holdings Co., Ltd. on EDINET, the FSA’s disclosure system (free to read)
Corporate number: 3011001108646 / Accounting standard: IFRS

  • Amounts: machine transcription of EDINET XBRL (no manual re-keying). Long narrative notes are text and not in the account list. Identifiers: machine transcription of the EDINET code list (retrieved 2026-08-22)
  • ★: position of the value calculated from disclosed figures among the 4,240 companies on this site, on a five-step scale. Not a judgement of the company. No forecasts usedThe formulas and how they are counted
  • No rank: net assets as a share of total assets, cash conversion and revenue per employee (size alone does not show quality). Industry median shown for comparison. Cash conversion of 100%: operating cash flow equal to operating profit
  • Profit-and-loss chart: only where “sales − cost of sales − SG&A = operating income” holds between disclosed values. Cost breakdown: the six largest SG&A items
  • Trend charts: key financial indicators of the annual securities report. Amounts in billions of yen (dividend per share in yen). Long-run chart joins reports filed in different years (newer report for overlapping years). Some items stop part-way after a change of accounting standard. A stock split changes the weight of one share. Consolidated and parent-only in separate tables
  • Revenue scale in the same industry: bars of revenue (disclosed values) of companies in the same industry grouping as the industry pages, largest first. Only the top three and the two companies either side of this one. Each company’s latest fiscal year. An order of size, not a ranking of quality or an investment view
  • Share prices: not published (no data source allows redistribution). No share-price-based indicators (such as the price earnings ratio) and no extension of past growth into the future
  • Average age, average length of service and average annual salary: the reporting company alone (the parent). At a holding company, a small head-office staff. Payout ratio (basic facts): dividend per share ÷ consolidated earnings per share, calculated here (the payout ratio in the annual securities report is the reporting company’s figure, on a different basis). Representative and founding date: gBizINFO (Ministry of Economy, Trade and Industry), some companies only
  • “Retrieved disclosed figures”: every value readable as a number from the annual securities report. Company-wide values only (no segment or other breakdowns)
  • Segment table: machine transcription of the segment information in the annual securities report. Business names as labelled by the company in its XBRL. No table where segment sales differ from the disclosed total by more than 1%. Adjustments, corporate, eliminations and “other” left out of the table and the share denominator, as they are not businesses
  • Breakdowns of amounts, not diagrams of how the business works. Who pays whom, and for what, is not in the disclosed figures; no lines drawn from guesswork